Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free NRXP Stock Alerts

NRx Pharmaceuticals (NRXP) Competitors

NRx Pharmaceuticals logo
$4.33 +0.19 (+4.59%)
Closing price 06/8/2026 04:00 PM Eastern
Extended Trading
$4.32 0.00 (-0.12%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NRXP vs. ACRS, CLYM, CABA, CTMX, and DNA

Should you buy NRx Pharmaceuticals stock or one of its competitors? MarketBeat compares NRx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NRx Pharmaceuticals include Aclaris Therapeutics (ACRS), Climb Bio (CLYM), Cabaletta Bio (CABA), CytomX Therapeutics (CTMX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does NRx Pharmaceuticals compare to Aclaris Therapeutics?

NRx Pharmaceuticals (NASDAQ:NRXP) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 4 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 15 mentions for Aclaris Therapeutics and 11 mentions for NRx Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.25 beat NRx Pharmaceuticals' score of 0.37 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NRx Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aclaris Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NRx Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. NRx Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Aclaris Therapeutics -832.58%-55.89%-38.49%

NRx Pharmaceuticals has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

NRx Pharmaceuticals has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M127.54-$28.62M-$1.09N/A
Aclaris Therapeutics$7.83M77.77-$64.92M-$0.56N/A

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 783.37%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 163.76%. Given NRx Pharmaceuticals' higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aclaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.13

Summary

NRx Pharmaceuticals and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Climb Bio?

NRx Pharmaceuticals (NASDAQ:NRXP) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

NRx Pharmaceuticals' return on equity of 0.00% beat Climb Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Climb Bio N/A -31.45%-30.39%

NRx Pharmaceuticals has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

NRx Pharmaceuticals has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M127.54-$28.62M-$1.09N/A
Climb BioN/AN/A-$59.85M-$0.78N/A

NRx Pharmaceuticals currently has a consensus price target of $38.25, indicating a potential upside of 783.37%. Climb Bio has a consensus price target of $21.64, indicating a potential upside of 100.89%. Given NRx Pharmaceuticals' higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Climb Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Climb Bio
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 6 more articles in the media than Climb Bio. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 5 mentions for Climb Bio. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Climb Bio's score of 0.27 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NRx Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Climb Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NRx Pharmaceuticals beats Climb Bio on 9 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Cabaletta Bio?

NRx Pharmaceuticals (NASDAQ:NRXP) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

NRx Pharmaceuticals' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Cabaletta Bio N/A -131.58%-96.46%

NRx Pharmaceuticals presently has a consensus target price of $38.25, suggesting a potential upside of 783.37%. Cabaletta Bio has a consensus target price of $15.50, suggesting a potential upside of 384.38%. Given NRx Pharmaceuticals' higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Cabaletta Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NRx Pharmaceuticals has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 8 mentions for Cabaletta Bio. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Cabaletta Bio's score of 0.23 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NRx Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cabaletta Bio
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NRx Pharmaceuticals has higher revenue and earnings than Cabaletta Bio. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M127.54-$28.62M-$1.09N/A
Cabaletta BioN/AN/A-$167.86M-$1.96N/A

Summary

NRx Pharmaceuticals beats Cabaletta Bio on 8 of the 14 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to CytomX Therapeutics?

NRx Pharmaceuticals (NASDAQ:NRXP) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

NRx Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. NRx Pharmaceuticals' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
CytomX Therapeutics -166.40%-36.61%-28.02%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NRx Pharmaceuticals has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 783.37%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 311.56%. Given NRx Pharmaceuticals' higher possible upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
CytomX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

CytomX Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M127.54-$28.62M-$1.09N/A
CytomX Therapeutics$76.20M6.57-$17.37M-$0.41N/A

In the previous week, NRx Pharmaceuticals had 8 more articles in the media than CytomX Therapeutics. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.59 beat NRx Pharmaceuticals' score of 0.37 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NRx Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
CytomX Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

CytomX Therapeutics beats NRx Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Ginkgo Bioworks?

NRx Pharmaceuticals (NASDAQ:NRXP) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

NRx Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. NRx Pharmaceuticals' return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A -202.92%
Ginkgo Bioworks -215.41%-56.08%-26.06%

NRx Pharmaceuticals has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 10 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.65 beat NRx Pharmaceuticals' score of 0.37 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NRx Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ginkgo Bioworks
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

NRx Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$1.23M127.54-$28.62M-$1.09N/A
Ginkgo Bioworks$170.15M3.10-$312.76M-$5.36N/A

NRx Pharmaceuticals presently has a consensus price target of $38.25, suggesting a potential upside of 783.37%. Ginkgo Bioworks has a consensus price target of $8.50, suggesting a potential upside of 5.26%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Ginkgo Bioworks on 10 of the 16 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRXP vs. The Competition

Export
MetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$149.99M$2.96B$6.48B$11.99B
Dividend YieldN/A1.70%2.67%5.58%
P/E Ratio-3.9717.6823.6923.74
Price / Sales127.54302.68514.83109.27
Price / CashN/A56.1726.9937.25
Price / Book-8.023.8310.436.78
Net Income-$28.62M$75.85M$3.57B$337.51M
7 Day Performance-5.93%-2.00%0.27%-2.34%
1 Month Performance40.58%-5.85%3.25%1.88%
1 Year Performance17.98%14.03%22.24%25.55%

NRx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRXP
NRx Pharmaceuticals
2.6882 of 5 stars		$4.33
+4.6%		$38.25
+783.4%		+32.4%$149.99M$1.23MN/A2
ACRS
Aclaris Therapeutics
3.8361 of 5 stars		$4.34
-4.6%		$11.29
+160.0%		+185.0%$635.47M$8.37MN/A100
CLYM
Climb Bio
3.11 of 5 stars		$11.80
+7.7%		$20.30
+72.0%		+674.8%$627.58MN/AN/A9
CABA
Cabaletta Bio
2.9546 of 5 stars		$3.67
-2.9%		$15.50
+322.3%		+29.0%$616.35MN/AN/A50
CTMX
CytomX Therapeutics
2.6393 of 5 stars		$3.45
-4.2%		$12.10
+250.7%		+11.4%$612.67M$35.54MN/A170

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel